title: Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction.
abstract: Salmeterol provides bronchoprotection against a number of constrictor stimuli for more than 12 h after a single dose. This effect could be due either to functional antagonism at the level of airway smooth muscle or to cell-stabilizing effects of the compound. In this study, we attempted to clarify this mechanism by comparing the effects of salmeterol (50 micrograms), salbutamol (200 micrograms) and placebo on the airway responsiveness to histamine (to assess functional antagonism), and to adenosine 5'-monophosphate (AMP) (to assess additional cell-stabilizing effects), 14 h after drug treatment. Thirteen patients with mild allergic asthma were studied in a double-blind, randomized protocol on 6 days, at least 48 h apart. Forced expiratory volume in one second (FEV1) was measured before and 15 min after inhalation of the study medication. Then, 14 h later (8 a.m. the following morning), a bronchoprovocation test with histamine or AMP was performed. We found that 14 h after inhalation, salmeterol still had a significant effect on FEV1 in comparison to placebo and salbutamol. The provocative dose producing a 20% fall in FEV1 (PD20histamine) was significantly increased after salmeterol, whilst the increase in PD20AMP did not reach significance. The shift in PD20 (in doubling dose steps) induced by salmeterol pretreatment was not different between histamine and AMP. We conclude that the prolonged protective effect of salmeterol occurs via an extended bronchodilating and functional antagonistic action and not via a cell-stabilizing effect.
authors.affiliation: Dept of Internal Medicine, University Hospital, Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Solèr
authors.forename: L
authors.initials: L
authors.lastname: Joos
authors.forename: C T
authors.initials: CT
authors.lastname: Bolliger
authors.forename: S
authors.initials: S
authors.lastname: Elsasser
authors.forename: A P
authors.initials: AP
authors.lastname: Perruchoud
mesh_terms: D000249:Adenosine Monophosphate; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D001249:Asthma / Q000503:physiopathology*; D001980:Bronchi / Q000187:drug effects; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006632:Histamine; D006801:Humans; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects; D000068299:Salmeterol Xinafoate; D013997:Time Factors
chemical_list: D001993:Bronchodilator Agents; D000249:Adenosine Monophosphate; D000068299:Salmeterol Xinafoate; D006632:Histamine; D000420:Albuterol